A platform company
Linking pharmaceutical innovation and
commercialization with strong product
lifecycle management capability
commercialization with strong product
lifecycle management capability
Focusing on unmet clinical needs, we collaborate with global biotech/biopharma to jointly develop first- or best-in-class innovative products.
Adhering to the patient-centered philosophy, we are dedicated to providing competitive products and services that enable the more effective diagnosis and treatment, whilst enhancing clinical practice to the ultimate benefit of the patient.
On September 25th, the list of “2023 Shenzhen Top 500 Enterprises” was officially announced. With outstanding performance in terms of overall scale, operating efficiency, creative capabilities and other comprehensive strengths, Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”), a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS” or the “Group”) was once again selected, ranking 143rd on the list. Shenzhen Kangzhe was also listed on the “Top 100 Social Contribution List of 2023 Shenzhen Top 500 Enterprises”. The “2023 Shenzhen Top 500 Enterprises” list is jointly released by the Shenzhen Enterprise Federation and Shenzhen Entrepreneurs’ Association. It is one of the most influential and authoritative rankings for Shenzhen enterprises. The list primarily evaluates participating companies based on various production and operation indicators where all the listing companies are the backbone of Shenzhen’s economic and social development. Due to Shenzhen’s rapid economic growth and the Group’s solid operational achievements, Shenzhen Kangzhe has been […]
We collaborate with global innovative companies in flexible structures to jointly build a pharmaceutical ecosystem in a sustainable and collaborative setting for the benefit of all stakeholders.
If you are interested in joining us, or curious about our business and products, please feel free to contact us.